Celcuity Inc.

About Celcuity Inc.

Celcuity is a clinical-stage biotechnology company focused on unraveling complex oncogenic activity and harnessing insights to develop new targeted therapies for cancer patients. Their mission is to discover previously undetectable cancer drivers and create drugs to treat them, providing options and delivering hope.

Products & Services

Gedatolisib:A pan-PI3K, mTORC1/2 inhibitor that comprehensively blocks the PI3K/AKT/mTOR (PAM) pathway, currently a lead candidate in clinical trials for breast and prostate cancer.

Cellular Analysis Platform:A third-generation platform that unravels complex oncogenic activity undetectable by molecular tests, used to identify new applications for targeted therapies.

gedatolisib

Specialties

Cancer Research Targeted Therapies Oncogenic Pathway Analysis PI3K/AKT/mTOR (PAM) Pathway Inhibition Clinical Trials for Breast and Prostate Cancer PI3K/AKT/mTOR pathway inhibitors targeted cancer therapies solid tumors breast cancer prostate cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 400000000 MR: - FA: $400,000,000 FAN: 400000000	D: 2026-06-03 FD: 2026-06-03	-
2	RT: Convertible Senior Notes (Debt) T: - FT: Convertible Senior Notes (Debt)	A: 500000000 MR: - FA: $500,000,000 FAN: 500000000	D: 2026-06-03 FD: 2026-06-03	-
3	RT: Debt T: - FT: Debt	A: 500000000 MR: - FA: 500 million USD FAN: 500000000	D: 2025-09-09 FD: 2025-09-09	2 investors
4	RT: Convertible Debt T: - FT: Convertible Debt	A: 175000000 MR: - FA: $175,000,000 FAN: 175000000	D: 2025-07-30 FD: 2025-07-30	-
5	RT: Convertible Senior Notes and Common Stock Offering T: - FT: Convertible Senior Notes and Common Stock Offering	A: 225000000 MR: - FA: $150,000,000 for Convertible Notes and $75,000,000 for Common Stock FAN: 225000000	D: 2025-07-28 FD: 2025-07-28	4 investors
6	RT: Underwritten Common Stock Offering T: - FT: Underwritten Common Stock Offering	A: 60000000 MR: - FA: $60.0 million FAN: 60000000	D: 2024-05-30 FD: 2024-05-30	6 investors
7	RT: Private Placement T: - FT: Private Placement	A: 50000000 MR: - FA: 50 million FAN: 50000000	D: 2023-10-18 FD: 2023-10-18	1 investors

Convertible Senior Notes Latest

2026-06-03

$400.0M

Convertible Senior Notes (Debt) 2026-06-03

$500.0M

Debt 2025-09-09

$500.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Brian Sullivan

Chief Executive Officer and Co-founder

L

Lance Laing, PhD

Chief Science Officer and Co-founder

V

Vicky Hahne

Chief Financial Officer

I

Igor Gorbatchevsky, MD

Chief Medical Officer

E

Eldon Mayer

Chief Commercial Officer

B

Brent Eilefson, JD

General Counsel

View 30 more team members with Pro

Unlock Full Team Directory

Recent News

Celcuity Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised